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Abstract
The progression of ovarian cancer, from cell transformation through invasion of normal tissue, relies on communi-
cation between tumor cells and their adjacent stromal microenvironment. Through a natural selection process, an
autocrine-paracrine communication loop establishes reciprocal reinforcement of growth and migration signals. Thus,
the cancer-activated stromal response is similar to an off-switch-defective form of the normal, universal response
needed to survive insult or injury. It is becoming clearer within the cancer literature base that tumor stroma plays a
bimodal role in cancer development: it impedes neoplastic growth in normal tissue while encouraging migration and
tumor growth in a co-opted desmoplastic response during tumor progression. In this review, we discuss this recip-
rocal influence that ovarian cancer epithelial cells may have on ovarian stromal cell–reactive phenotype, stromal cell
behavior, disrupted signaling networks, and tumor suppressor status in the stroma, within the context of cancer
fibroblast studies from alternate cancer tissue settings. We focus on the exchange of secreted factors, in particular
interleukin 1β and SDF-1α, between activated fibroblasts and cancer cells as a key area for future investigation and
therapeutic development. A better understanding of the bidirectional reliance of early epithelial cancer cells on acti-
vated stromal cells could lead to the identification of novel diagnostic stromal markers and targets for therapy.
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Introduction
Epithelial ovarian cancer is the most lethal gynecologic malignancy
among women in the United States and other industrialized nations,
resulting in approximately 15,000 deaths and nearly 22,000 new cases
in 2009 [1]. Survival rates approaching 90% are achievable among
ovarian cancer patients diagnosed at an early stage. Nonetheless, early
detection is challenging because nonspecific symptoms of early ovarian
lesions go unnoticed until the patient presents with an abdominal dis-
tension due to late-stage tumor growth and accumulation of ascites
fluid. Despite extensive surgical debulking followed by an aggressive
platinum/taxane–based chemotherapy and radiotherapy regimen, re-
currence and dissemination occurs frequently. Late-stage high-grade
ovarian cancer metastasizes rapidly to the omentum and surrounding
abdominal organ surfaces [2]. Several studies have noted that the de-
fined histological categories of ovarian carcinoma tend to associate with
particular underlying molecular mechanisms, including genetic muta-
tions (e.g. KRAS, p53, BRCA1/2), allelic amplification, and carcinogens
[3–6]. Thus, specific genetic mutations among diverse histomorphologic
ovarian cancer subtypes allow pathologists to identify and diagnose tu-
mor specimens by microscopy [7,8]. However, the origin and causes of
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ovarian carcinoma, particularly the cooperative interaction with an ac-
tivated stromal tumor microenvironment, remain to be elucidated.
Ovarian tumorigenesis is initiated by the malignant transformation
of epithelial cells derived from the pelvic müllerian duct, likely origi-
nating either from the continuous outer ovarian surface epithelial cell
layer or from fallopian tube epithelial cells [9]. Of note, there is accu-
mulating evidence implicating fallopian tube epithelial cells, especially
those derived from the fimbriated ends, as the likely origin for high-
grade serous carcinoma [10]. In contrast to the dedifferentiation ob-
served after transformation in most epithelial cancers, ovarian cancer
progression results in distinct histological subtypes (or histotypes) that
are reminiscent of the differentiated morphology of the surrounding
gynecological anatomy: high-grade and low-grade serous, endome-
trioid, clear cell, mucinous carcinoma, and tumors of low malignant
potential [11]. These distinct histotypes allow clinicians to monitor
for increased levels of serum markers for early detection of ovarian
cancer, such as CA125 [11]. Monitoring secreted communication
signals sent by ovarian epithelial cancer cells is a mainstay of ovarian
cancer patient follow-up; however, these signals are only a part of the
epithelial-stroma communications network.
The histomorphologic complexion of ovarian cancer varies according
to the histotype and grade of the developing carcinoma. Low-grade
serous carcinoma displays a consistent, differentiated papillary growth
architecture, with a key feature being uniform nuclei and numerous
psammoma bodies [12] and a comparatively high proportional contri-
bution of cancer stromal cells and expansive tumor microenvironment
(Figure 1, A and B, fibroblasts indicated by black arrows), highlighted
by the reactive stroma marker α-smooth muscle actin (α-SMA) (Fig-
ure 1, C and D). Low-grade and high-grade serous carcinomas likely
initiate by means of independent genetic pathways, as evidenced by
molecular analysis, clinical appearance, and morphologic features
[13]. High-grade serous carcinoma is characterized by a distinctive
growth pattern of highly stratified and fenestrated epithelium, a very
high mitotic rate, a threefold variation in nuclear size and pleomor-
phism [12], and a relatively low proportion of cancer-associated stromal
cells (Figure 1, E-H , fibroblasts highlighted by black arrows and positive
staining for α-SMA immunohistochemical staining; nuclear atypia
highlighted by red arrows). Endometrioid carcinoma, so named for a
resemblance to the cribriform morphology of the endometrium, exhi-
bits clusters of tube-shaped glandular lumens that are lined by stratified,
potentially squamous (in the case of morules), epithelium lacking
mucinous deposits [12], and displays a moderate to a low proportion
of cancer-associated stroma. Mucinous carcinoma is a heterogeneous
designation, ranging in morphology from expansile glandular to multi-
lobular, pilus-like, papillary, to a solid infiltrative epithelial phenotype,
with a key unifying feature being extensive mucus-like deposition from
goblet cells [14], and a relatively large proportional contribution of stro-
mal cells. Clear cell carcinoma displays characteristic microscopic fea-
tures that include multiple complex papillae with densely hyaline basal
lamina cores and occasional hyaline bodies, with epithelial cells display-
ing enlarged, clear cytosolic bodies [12], and a relatively dense extra-
cellular matrix (ECM) that lacks the high fibroblastic concentration
of other histotypes. Overall, the relative proportion of stroma in ad-
vanced ovarian cancer ranges from 7% to 83% of tissue composition,
with a median of 50% contribution, and this estimation does not vary
significantly according to histotype, International Federation of Gyne-
cology and Obstetrics stage, or grade [15].
The progression of ovarian cancer tumor cell populations, from cell
transformation through invasion of normal tissue and eventual metasta-
sis, likely relies on a critical secretory reciprocal communication with
their adjacent stromal microenvironment. A component that is vital
to our understanding is how synergistic communication signals sent
by cancer epithelial cells are interpreted and translated into a non–
cell-autonomous secretion- and growth-activating response in cancer-
associated fibroblasts (CAFs). Deciphering the role of this paracrine
and reciprocal cancer-stromal communication network in the early ini-
tiatory stages of ovarian cancer is fundamental to understanding ab-
normal acute and chronic fibroblast activation. Although multiple cell
types are present in the stromal ECM compartment of the various ovar-
ian cancer histotypes, CAFs have been shown to play a critical role in
determining overall clinical outcome of cancers throughout the body.
Gene expression profiling of CAFs in multiple cancers has identified
genes that are differentially expressed in comparison to normal fibro-
blasts, and these genesmay shed light onmalignant epithelium-activated
fibroblast secretory interaction and cooperative cellular behavior. Fur-
ther, molecular indicators of an activated ovarian CAF state may enable
the development of non–cancer cell markers for early-stage detection of
the extent of aggressive growth promotion andmay thus yield additional
candidates for therapeutic intervention. Therefore, in this review, we
focus on putative intracellular and intercellular signaling activators
and pathways in CAFs, including ovarian, that affect communication
with cancer cells and their normal neighbors. First, we give a brief per-
spective on the role of the stromal microenvironment in cancer. Then,
we discuss the influence that ovarian cancer epithelial cells have on
stromal cell behavior, disrupted pathway signaling in CAFs of various
cancer types that may be involved in ovarian CAFs, and tumor suppres-
sor status in CAFs of ovarian, breast, and prostate carcinomas. Finally,
we summarize the status of identifying ovarian CAF contribution to
ovarian carcinoma and discuss future hypotheses. Overall, our focus is
on the exchange of secreted factors between activated fibroblasts and
cancer cells as a key area for future investigation and therapeutic devel-
opment in ovarian cancer treatment.
A Historical Perspective: Selective Activation in
the Tumor Stromal Microenvironment
Although some cancers develop stromal independence through epithelial-
mesenchymal transition (EMT) before metastasis, successful tumori-
genic initiation likely requires a coevolutionary stimulus of the stromal
microenvironment whereby cancer-associated stromal cells receive
acute, prolonged activation signals to form a reactive, secretory pheno-
type [16–18]. Activated stromal response in cancer was first described
in 1979, when Seemayer et al. [19] observed that myofibroblasts, or
activated fibroblasts, played a critical role in the desmoplastic response
to neoplastic mammary carcinoma. In 1983, an initial distinction was
made between themigratory behavior of CAFs and that of normal fibro-
blasts, when Mensing et al. [20] noted that dermal tumor-associated
fibroblasts displayed a more differential chemotactic response to fibro-
nectin than did normal fibroblasts. Shortly thereafter, Strauli et al. [21]
and Haemmerli et al. [22] used the rabbit V2 carcinoma model and
observed that V2 cancer cell invasion into rabbit mesentery was medi-
ated, in part, by a multiplication of co-opted connective tissue cells and
enhanced ECM deposition, characterized by a transdifferentiation of
recruited fibrocytes (circulating fibroblast progenitor cells) into myo-
fibroblasts. In the late 1980s, studies showed that interactions between
lung tumor cells and lung tumor–associated fibroblasts are likely to
play a critical role in ECM degradation, as well as in the selection of
tumor cells that eventually metastasize [23], and that activated im-
mune cells and tumor cells increased the ECM-degrading capacity of
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normal lung fibroblasts [24]. In 1989, Carnemolla et al. [25] observed
an oncogenesis-specific secretion from activated stroma: the alterna-
tively spliced fibronectin isoform B was expressed only by transformed
lung fibroblasts. In a seminal publication, Nagy et al. [26] noted that
generation of generic fibrinolytic tumor stroma is perpetual and critical
to successful tumorigenesis and, therefore, cancer resembles a wound
that is unable to heal. Thus, stromal fibroblasts possess a bimodal func-
tional role in tissue biology. Normal stromal fibroblasts can impede the
Figure 1. Histomorphology and interaction of ovarian cancer epithelial cells and CAFs. Themorphologic characteristics of low-grade serous
ovarian carcinoma include a papillary growth architecture and uniform nuclei (A and B; hematoxylin and eosin stain), with a comparatively
high proportional contribution of cancer stromal cells identified by immunohistochemistry for α-SMA (C and D), a marker that highlights
activated reactive CAFs (indicated by black arrows). The altered histomorphology of high-grade serous carcinoma is characterized by a
distinctive growth pattern of stratified epithelium with high mitotic rate and a threefold variation in nuclear size and pleomorphism (E
and F; hematoxylin and eosin stain). Nuclear atypia are highlighted by red arrows. High-grade serous carcinoma displays a high proportion
of CAFs (G and H) highlighted here by immunohistochemistry for α-SMA (black arrows). Scale bars, 50 μm.Magnification, ×200 (A, C, E, and
G); ×400 (B, D, F, and H).
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abnormal growth of preneoplastic epithelial cells in a variety of normal
tissues (Figure 2). However, stromal fibroblasts can also be protumori-
genic, responding in a co-opted desmoplastic response where they en-
courage both migration and invasion of epithelial cancer cells [27–31]
(Figure 2, last panel ).
These seminal publications have led to the viewpoint that aggressive
malignancies selectively perpetuate within stromal microenvironments
that are richly populated with activated and reactive cells (CAFs, myo-
fibroblasts, angiogenic precursors, immune cells, and others), which can
be collectively reprogrammed to support overall tumor growth [32]. A
functional, reciprocal interaction is now currently acknowledged be-
tween tumor cells and the tumor microenvironment, wherein tumor
stromal cells very likely facilitate a critical role during both tumor cell
initiation and growth progression [33]. Thus, epithelial cancers are no
longer considered as isolated clusters of transformed epithelial cells that
invade passive, uninvolved neighboring regions, namely, stroma. An
alternate perspective has acquired increased stature within the past
few decades: a tumor-promoting stromal microenvironment selectively
facilitates, through reciprocal juxtacrine communication, the prolif-
eration and invasion of epithelial cancer cells. Therefore, cancer cells
that activate and maintain a protumorigenic, anti-immunogenic niche
would retain a selective growth advantage [32]. This natural selection
process is strikingly similar both to Dvorak’s wound healing analogy
and to some processes in embryogenesis [34], where an autocrine-
paracrine communication loop establishes reciprocal reinforcement of
growth and migration signals, thereby limiting healing or development
(Figure 2). This perspective, which has been pioneered by Dvorak [36],
Rowley [18], and others, implies that the cancer-activated reactive stro-
mal response is an off-switch-defective form of the normal, universal
biologic response needed to survive tissue insult or injury [35].
Cancer Epithelial Cell Activation of the Reactive
Stromal Phenotype in Ovarian and Other Cancers
Activation of fibroblasts to a myofibroblast phenotype through recip-
rocal paracrine interaction with neoplastic and transformed epithelial
cells has been observed in several in vitro studies using ovarian cells.
For example, medium conditioned by SKOV3 cells, an established,
malignant ovarian cancer cell line, induced transdifferentiation of
normal ovarian fibroblast to a myofibroblast phenotype characterized
by elevated reactive stroma marker α-smooth muscle actin (α-SMA)
[37]. Further, the authors identified chloride intracellular channel-like
4 (CLIC4) and various reactive oxygen species as potential SKOV3-
secreted factors that could yield the same ovarian myofibroblast stromal
phenotype in vitro [37]. Analogously, breast carcinoma progression
Figure 2. The contribution of CAFs tomalignant progression of ovarian cancer. (A) Normal ovarian tissue is composed of ovarian or fallopian
tubal epithelial cells and an extracellular microenvironment consisting of quiescent fibroblasts and other supportivemesenchymal cell types
that collectively inhibit inappropriate or preneoplastic epithelial proliferation. (B) Transition fromnormal to preneoplastic, or neoplastic, ovarian
or fallopian tubal epithelial cells involves reciprocal secretory communication with activated myofibroblasts, whether tissue resident or
recruited fromcirculation. (C) Progression tomalignant ovarian cancer relies, at least initially, on a secretory co-opting of ovarianCAFs through
exchangeof intercellular secreted factors (e.g., chemokines like IL-1β andGRO-α)withCAFs to facilitate dissemination to the omentum.CAFs
may directly facilitate this metastatic movement, although it is likely that EMT of ovarian or fallopian tumor cells provides a reservoir of
secretory, ECM-digesting, migratory CAF-like cells.
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was associated with increased expression of CLIC4 in breast cancer–
associated stromal cells, relative to a reduced expression in normal breast
epithelial cells [38].Moreover, CLIC4 induced up-regulation ofα-SMA
in breast cancer CAFs in vitro, and CLIC4-overexpressing breast myo-
fibroblasts stimulated xenograft tumorigenesis [38]. A recent study
showed that normal human fibroblasts selectively inhibited proliferation
of prostate and lung cancer–derived tumor cells in a direct cell contact–
dependent manner [39]. Similarly, it was shown that normal human
breast–associated fibroblast inhibition of tumorigenic breast cancer cells
was significantly enhanced in direct coculture compared with indirect
coculture, relative to breast CAF stimulation of breast tumor cell prolif-
eration [40]. Ovarian stromal cell type is critical in determining whether
metastasis occurs because it was observed that fibroblasts derived from
the omentum, the richly vascularized fatty subperitoneal layer draping
the ovaries, augmented ovarian cancer cell adhesion and invasive behav-
ior, whereas omentum-derived mesothelial cells functionally inhibited
ovarian cancer cell aggressiveness [41]. Very recently, a study used the
reactive stroma markers α-SMA and fibroblast activation protein (FAP)
to correlate the presence of ovarian CAFs to ovarian cancer patient clini-
cal outcome, finding a significant association with the occurrence of
lymph node and omentum metastases, as well as elevated lymphatic
vessel density and microvessel density [42]. Moreover, the authors
showed that CAFs isolated from ovarian cancer tissue induced ovarian
cancer cell invasion and migration in vitro [42]. These data demonstrate
that ovarian CAFs are directly related to ovarian cancer progression and
metastasis. However, more work must be done in identifying specific
ovarian cancer epithelial cell–secreted factors that directly facilitate
ovarian fibroblast activation and protumorigenic and prodissemination
secretory activation.
Activated CAFs, across most cancers, secrete a wide variety of
growth factors, chemokines, collagens, and matrix-modifying enzymes,
collectively supplying a communication network and altered three-
dimensional ECM scaffold that governs the proliferation of cancer cells,
tumor invasion, and metastasis across tissue types [43]. Therefore, it is
of interest whether the proportion of tumor stroma cells in the tumor
microenvironment within cancer reflects a mutual growth pattern. In-
terestingly, the impact of the proportional representation of the stromal
compartment on tumor invasiveness and histological dedifferentiation
has been studied in prostate disease [44], colorectal cancer [45], breast
carcinoma [46], and pulmonary carcinoma [47]. Specifically, in ovarian
cancer, component aspects of the tumor stromal compartment have
been described as prognostic patient severity indicators, including blood
vessel architecture [48], extent and type of inflammatory cells [49], and
ECM-interacting, ovarian fibroblast–secreted factors, including the
glycosaminoglycan hyaluronic acid [50] and a hyaluronan-partner
glycoprotein versican [51]. In another study, conditioned medium from
ovarian clear cell carcinoma (ES-2) cells included paracrine-acting cyto-
kine signals, which upregulated ovarian fibroblast transcription of
urokinase-type plasminogen activator, a key enzyme in cancer cell in-
vasion and metastasis [52]. Moreover, parallel epithelial and stromal ex-
pression patterns were observed in tissue samples from patients with
aggressive ovarian cancer for the paracrine-secreted markers cyclooxy-
genase 1 (COX-1), COX-2, microsomal prostaglandin E synthase-1
(mPGES-1), and EP1-2, factors that collectively promote angiogenesis
and proliferation while simultaneously discouraging apoptosis [53].
Moreover, the relative stromal abundance and composition of the ovar-
ian tumor microenvironment itself was found to have an independent,
statistically significant prognostic value, particularly in late-stage epithe-
lial ovarian cancer patients [15]. These data demonstrate that women
with a high proportion of ovarian tumor stroma display decreased overall
survival. Interestingly, this study did not identify a significant relation-
ship between the proportion of ovarian tumor stroma and ovarian tumor
histotype [15]. This suggests that the proportion or percentage of ovar-
ian tumor stroma may functionally activate a universal ovarian stromal
communication mechanism that is independent of the gynecological
tissue or cell type of origin. The authors theorized that decreased survival
of ovarian cancer patients with a high proportion of cancer stroma may
potentially reflect an insufficient penetration, or altered resistancemech-
anism, to drug treatment based on cell adhesion [15]. Further, another
study focusing on ovarian carcinosarcomas identified that patients with
late-stage disease and a high percentage of ovarian cancer stroma dis-
played reduced survival and poor clinical outcome [54]. Therefore, it
is becoming clear that ovarian cancer cell–secreted factors, within the
context of altered interaction from cell-cell communication, directly
promote the activation of stromal cell secretion, migration, and function
(Figure 3A).
Critical Factors Mediating the Activated Response
of CAFs from Diverse Cancers, Including
Ovarian Carcinoma
Several recent reviews have focused on the therapeutic potential of tar-
geting the activated cancer–associated stromal compartment [55,56].
Some putative CAF markers that have been correlated with cancer in-
cidence or progression in other cancer types are also likely to play a crit-
ical role in ovarian tumorigenesis (Figure 3B). It has been shown that
an oncogenic cancer epithelium results in a tumor microenvironment
replete with inflammatory mediators, growth factors, matrix remodel-
ing enzymes, and angiogenic factors [31,57,58]. The net result of this
milieu leads to a recruitment of associated, activated fibroblasts, osten-
sibly due to reciprocal interaction through inflammatory factors.
Chemokines and Cytokines
Generalized inflammation of the female peritoneum, typically associ-
atedwith ovarianmicrometastases and stromal invasion, has been tied to
elevated expression of IL-8 [59,60]. Moreover, up-regulation of tumor-
regulated IL-6, IL-8, and IL-1β is associated with the inflammatory
network, promoting tumorigenesis, angiogenesis, and metastasis in var-
ious cancers, including those of the breast, prostate, and pancreas [61].
Our laboratory has identified several stromal-activating chemokines, in-
cluding IL-6, IL-8, and growth-regulated oncogene α (GRO-α), which
are significantly elevated in transformed, neoplastic ovarian surface
epithelial cells [62]. Moreover, we have demonstrated that GRO-α–
overexpressing ovarian fibroblasts with inhibited p53 significantly in-
creased ovarian cancer epithelial proliferation and tumorigenic growth
in a mouse xenograft model [63]. Furthermore, our laboratory demon-
strated that IL-1β is significantly elevated in Ras-transformed ovarian
carcinoma cells [62], and we have evidence that ovarian cancer cell–
secreted IL-1β attenuates p53 in neighboring ovarian fibroblasts (un-
published observations). As a comprehensive signaling axis, the IL-1β/
IL-1 receptor 1 (IL-1R1) activates a defined set of downstream signaling
effectors and binding partners [64]. IL-1R1 axis effectors include several
isoforms of the IL-1 receptor–associated kinases (IRAK proteins), as
well as the protein-protein interaction effector tumor necrosis factor-α
receptor–associated factor 6 [65–67]. Nuclear localization of IRAK-1
has been correlated with enhanced malignancy in lung cancer [68]
and prostate cancer [69] and has been shown to bind directly to the IκBα
promoter and enhance binding of nuclear factor-κB (NF-κB) p65
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subunit in skin fibroblasts [70]. In breast cancer, CAFs were found to
initiate and mediate tumorigenesis through a macrophage-recruitment
inflammatory signature that was highly dependent on breast CAF
NF-κB signaling [71]. Thus, as pathway effectors activated by the IL-1β/
IL-1R1 signaling axis function both in the nucleus and cytoplasm of
fibroblasts, these IL-1R1 pathway mediators may perhaps be responsi-
ble for eliciting IL-1β–mediated transcriptional or translational attenu-
ation of tumor suppressors in ovarian CAFs (Figure 2B).
Figure 3. Model of critical pathways andmechanisms in the activation of ovarian fibroblasts by secretory interaction with neoplastic ovarian
cancer cells. (A) Secreted activation signals, such as IL-1β, IL-6, and IL-8 or GRO-α, from neoplastic ovarian or fallopian tubal cancer epithelial
cells stimulate a stromal phenotypic shift from quiescent to activated ovarian or omental fibroblasts. Activated CAFs are proliferative, are
migratory, and secrete a variety of ECM-restructuring factors (e.g., FAP-1α, urokinase-type plasminogen activator), soluble cancer-activating
chemokines (e.g., SDF-1α), and cell surface proteins (e.g., CLIC4). Cancer cell–mediated fibroblast activation selectively promotes tumor
angiogenesis, adhesion, migration, and invasion while reducing apoptotic inhibition. (B) Activation of chemokine receptors on ovarian CAFs,
including IL-1 receptor 1 (IL-1R1), CD126/CD130, and CXCR2, by ovarian cancer cells likely activates intracellular signaling cascademediators
in ovarian CAFs including IL-1R–associated kinases (IRAK) 1, 2, and 4; tumor necrosis factor α receptor–associated factor 6 (TRAF-6); IL-1–
induced activation of c-Jun N-terminal kinase and NF-κB; as well as the c-Jun N-terminal kinase/Janus kinase (JAK)/STAT family members. In
ovarian CAFs, these signalingmediatorsmay activate AKT/extracellular signal–regulated kinase 1/2 (ERK1/2)/RBPJκ–mediated transcriptional
up-regulation of ovarian CAF-secreted factors that impact epithelial ovarian cancer tumor cell aggressiveness, including the glycoprotein
tenascin-C, protease FAP-1α, and myriad interleukins, especially IL-8. In parallel, downstream signals in ovarian CAFs from chemokine-
activated receptors facilitate transcriptional or translational inactivation of tumor suppressors, like p53, by yet uncharacterizedmechanisms.
Once tumor suppressors like p53, PTEN, or Rb are inhibited/inactivated, two intracellular pathways are initiated that are not understood at
all: 1) increased cellular production of chemokines, including IL-1β, IL-8, IL-6, and SDF-1α, and 2) chemokine receptors, like IL-1R1, are up-
regulated. Collectively, ovarian fibroblast activation leads to paracrine ovarian cancer cell stimulation and autocrine stimulation, co-opting a
desmoplastic-like stromal response for tumor cell initiation, survival, and inappropriate growth.
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Stromal-derived factor-1α (SDF-1α), also called chemokine (CXC
motif ) ligand 12 (CXCL12), is a glutamic acid–leucine–arginine motif-
negative chemokine lacking chemotactic influence on immune cells
[71]. SDF-1α signals primarily through the CXC chemokine receptor
4 (CXCR4) [58], and the SDF-1α/CXCR4 signaling axis is deregu-
lated in multiple malignancies, playing a critical role in promoting
cancer cell migration and metastasis of many tumor types, including
leukemia [72] where there is a preponderance of SDF-1α publications,
ovarian and cervical cancer [73–77], prostate [78], breast [79], liver
[80,81], colorectal [82], pancreatic [83], lung [84], and multiple mye-
loma [85]. Moreover, a few recent articles address the potential for
CAF expression of SDF-1α contributing to cancer progression [86–
89]. Several reports have discussed the involvement of the SDF-1α/
CXCR4 signaling axis in epithelial ovarian cancer cell lines in vitro, or
using tissue immunohistochemistry quantitation to determine predictive
ability [77,90–94]. One recent publication showed elevated peritoneal
dissemination in vivo after intraperitoneal nude mouse injection of
5 million ES-2 cells, a clear cell ovarian cancer line, with daily injection
of systemic, exogenous high-concentration SDF-1α [95]. Moreover, a
recent review of the role of the SDF-1α/CXCR4 signaling axis in ovarian
cancer cell stated that SDF-1α overexpression coincides with ovarian can-
cer cell proliferation and metastasis, and identified several recently devel-
oped therapies that target either SDF-1α or CXCR4 [96]. CXCR4 is
expressed not only in cancer cells; it can also be upregulated in fibroblasts
through PDGF, IL-1β, and HIF-1α and can be attenuated in fibroblasts
by activation of phosphatidylinositol 3-kinase and mammalian target of
rapamycin [97,98]. Both exogenous IL-1α and oral squamous cell car-
cinoma (OSCC)–conditioned medium stimulated SDF-1α expression
in CAFs, whereas CAF-conditioned medium stimulated OSCC cell in-
vasion in vitro [99]. However, when exogenous SDF-1α was applied to
OSCC cells in the absence of CAFs, the pattern of invasion in culture
was different from that with CAF-conditioned medium, implying a
complex multifactor intracellular communication [99]. Relating this
chemokine pathway to tumor suppressor function, p53 can repress the
expression of SDF-1α in embryonic lung fibroblasts [100], likely result-
ing in a microenvironment less conducive to tumor cell migration and
survival. p53 activation directly attenuated invasion and migration of
breast cancer cells through repressed SDF-1α gene transcription [100].
Thus, loss of p53 expression in CAFs may contribute to inappropriate
activation of the CXCR2/4 signaling axis in tumorigenesis (Figure 2B).
However, the functional role of the SDF-1α/CXCR4 signaling axis in
ovarian CAFs, and whether this directly impacts ovarian epithelial tumor-
igenesis, migration, and metastasis, has not been completely addressed
and warrants further investigation.
Activation-Associated Fibroblast Factors
Fibroblast activation protein-1α (FAP-1α), a cell surface protease
with dipeptidyl peptidase and endopeptidase activity, is expressed by
stromal cells in several different cancers [57] and has been used as a clini-
cal therapeutic target by multiple immunoconjugate clinical studies in
multiple cancer types [101–104]. FAP-1α is induced in ovarian fibro-
blasts by exposure to conditioned medium from a metastatic ovarian
cancer cell line, HO-8910PM, or to exogenous factors TGF-β1 and
IL-1β [105]. Once elevated, FAP-1α promotes proliferation, adhesion,
and migration of metastatic ovarian cancer cells [105]. Similarly, a novel
category of activated stromal response was identified in OSCC, termed
nemosis, that correlates stromal expression of progrowth and proinflam-
mation factors (α-SMA, FAP-1α, and fibroblast-specific protein-1α
[FSP-1α]) with in vitro tumor cell function [106]. Thus, FAP-1α pres-
ents an interesting opportunity for further study in ovarian tumor stro-
mal biology.
Tenascin-C is a secreted glycoprotein that is elevated in the stromal
microenvironment of epithelial cancers, is likely to act by decreasing the
formation of cell adhesion complexes thereby promoting proliferation
and migration, and is considered a potential oncogene (reviewed in
Hsia and Schwarzbauer [107] and Orend [108]). In a powerful multi-
variate index assay using serum from patients with ovarian cancer and
controls, tenascin-C was included as 1 of 11 analytes (selected from 104
candidates) that could distinguish benign from malignant ovarian con-
ditions with sensitivity and specificity of up to 90% [109]. Similarly,
tenascin-C was identified as one of four distinguishing factors in an
immunohistochemistry-based survival tree model of intrahepatic cho-
langiocarcinoma [110]. Furthermore, our data show that intense stro-
mal expression of tenascin-C correlates with shorter survival duration
in patients with all ovarian cancer histotypes, and specifically in those
with high-grade serous tumors (unpublished observations).
Originof theOvarianCancerTumorMicroenvironment
Although the origin of stroma in ovarian cancer is largely unknown,
recent evidence frommouse xenograft models of multiple human cancer
cell types (including ovarian) points to activation of tissue-resident fi-
broblasts, recruitment of hematopoietic precursors or mesenchymal
stem cells (MSCs) [111,112], and promotion of senescent fibroblasts
[63,113]. Using dynamic magnetic resonance imaging, it was observed
that recruited fibroblasts formed a functional tumor neovasculature
at the rim of ovarian cancer nodules, thereby identifying an activated
ovarian fibroblast response with potential therapeutic implications
[114]. In ovarian cancer, it was recently reported that ovarian cancer–
derived lysophosphatidic acid stimulates differentiation of human adi-
pose tissue–derived MSCs (hADMSC) to CAFs, elevating the expres-
sion of SDF-1α through a TGF-β1–mediated autocrine stimulation of
Smad2 [115]. Moreover, the authors demonstrated that treating
hADMSCwith ovarian cancer patient ascites fluid, or with conditioned
medium from ovarian cancer cells, induced expression of the reactive
stroma marker α-SMA and phosphorylation of Smad2 and that this
effect could be abrogated by pretreating with an lysophosphatidic acid
receptor antagonist [115]. Also in ovarian cancer, the pro-inflammatory
peptide, LL-37, a C-terminal peptide fragment of human cationic anti-
microbial protein 18, was shown to be overexpressed in ovarian cancer
tissue and to directly stimulate ovarian cancer cell migration in vitro
[116]. This same group recently demonstrated that in vivo neutraliza-
tion of LL-37 significantly inhibited xenograft tumor growth overall,
likely through reduced engraftment of MSCs into ovarian tumor xeno-
grafts and disruption in the establishment of a tumor fibrovascular
network [117]. Thus, LL-37 may facilitate ovarian tumor progression
through recruitment of ovarian CAF progenitor cells that express pro-
angiogenic factors. Pertaining to an alternate origin for ovarian cancer
tumor microenvironment, senescent ovarian fibroblasts significantly
increased in vitro migration of cMyc-mediated early neoplastic ovarian
surface epithelial cells compared with coculturing with presenescent
ovarian fibroblasts [118]. Further, this study demonstrated that senes-
cent ovarian fibroblasts stimulated early neoplastic ovarian epithelial cell
anchorage–independent colony growth, as well as increased prolifera-
tion and induced nuclear atypia in a three-dimensional spheroid in vitro
model [118]. Thus, the etiology underlying the development of epithe-
lial ovarian neoplasia may depend on the accumulation of senescent
(or loss of presenescent) ovarian fibroblasts. Therefore, further work
in identifying the likely multifactorial source of ovarian carcinoma–
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associated stromal cells has therapeutic implications in recognizing and
targeting stromal-mediated tumor activation in early-stage ovarian
cancer patients.
Tumor Suppressor Status in CAFs
Of the many tumor suppressors characterized, p53 is the only one
for which inactivation has been well substantiated in a variety of epithe-
lial cancers and has been shown in a subset of cancer stromal cells
[31,119]. The existence of genetic alterations in CAFs is controversial.
Studies have identified distinct genetic alterations in breast and squa-
mous CAFs, ranging from mutation of critical tumor-suppressor genes
like phosphatase and tensin homolog (PTEN) and TP53, to loss of
heterozygosity, or alterations in allelic copy number [120–125] (Fig-
ure 3B). Conversely, other studies have not identified similar changes
in breast or ovarian CAFs, and no agreement on a unifying genetic al-
teration in all CAFs exists to date [126–128]. Several reports focusing on
breast and prostate CAFs have identified epigeneticmechanisms, such as
promoter methylation, that correlate with poor clinical factors [129–
131], which need to be addressed in ovarian CAF biology. p53 function
is intriguing because it activates non–cell-autonomous functions that
likely contribute to tumor suppression through communication with
normal fibroblasts. For example, p53-dependent secreted factors such
as PTGF, a transforming growth factor-β (TGF-β) family member
[132], IGF-BP3 [133], and other factors have been shown to facilitate
stromal cell–mediated inhibition of prostate cancer cell growth [134].
Human breast cancer tumor cell injections using p53-null mice resulted
in markedly increased tumor growth rates, relative to growth rates after
injection into normal, p53-intact control mice [121], indicating that
an activated host stroma with incapacitated p53 is tumor promoting.
Indeed, p53 inactivation mutations were reported to occur in the fibro-
blastic stroma of both colon and breast cancers [122,124,135]. More-
over, TP53 mutational status may be a predictor of CAF-mediated
resistance to cytotoxic chemotherapeutics, although this response is
highly variable across different tumor types [136,137]. Furthermore,
breast carcinoma CAFs were recently shown to possess a nonmutated,
but functionally deficient, form of p53 [138,139]. The question of
whether genetic aberrations in CAFs could be the basis of the cancer-
promoting phenotypes of ovarian CAFs remains to be resolved. We
believe that irrespective of the tissue source, how close the stromal cell
extraction/microcapture site is to the tumor determines whether one
observes the genotypic mutational status of true CAFs, or instead nor-
mal fibroblasts.
Although there are very few publications addressing p53 regula-
tion of secreted and membrane-bound factors in fibroblasts or CAFs,
it is assumed that publications describing p53-mediated mechanisms
in epithelial cells will likely translate into similar mechanisms in
fibroblast p53 regulation. Elevated expression of both wild-type
p53 and wild-type Rb in HeLa cells repressed promoter constructs
for IL-6 and c-Fos [140]. Wild-type p53 mediated repression of
the chemokine receptor 4 in breast cancer cells, which was negated
by the expression of the p53 V143A dominant negative mutant, and
cancer-specific p53 phospho-mutants R175H or R280K [141]. p53-
mediated repression of EMMPRIN, a transmembrane glycoprotein
that promotes survival, invasion, and metastasis through induced
MMP expression, led to a decrease in MMP-9 in prostate cancer cells
[142]. Specifically addressing p53 mutation in CAFs, colon CAFs over-
expressing an alternate human p53 isoform, Δ133p53, displayed re-
pressed miR-34a (a p53-activated microRNA that helps to facilitate
senescence) and extended cellular replication in vitro [143]. Therefore,
the cause and impact of p53 inhibition in ovarian CAFs, and whether
this induces a reciprocal, intercellular communication with neoplastic
ovarian epithelial cells to promote tumorigenesis and metastasis, have
yet to be characterized.
Anecdotal evidence suggests that, in the absence of focal adhesion ki-
nase (FAK), expression of Pyk2, an inhibitor of p53, prevented cisplatin-
mediated apoptosis in human foreskin fibroblasts [144]. Further, a
recent preclinical mouse xenograft study using an ATP-competitive re-
versible inhibitor of FAK and FAK2 (Pyk2) showed a potent inhibition
of in vivo metastatic prostate cancer growth [145]. In another mouse
model of prostate cancer, increased epithelial tumorigenesis led to a no-
ticeable selection for p53-inhibited stromal cells [146], suggesting that
tumor cell behavior may directly control the tumor suppressor status of
stromal cells. Furthermore, it was shown recently that immortalized,
nontumorigenic lung epithelial cells expressing mutant H-Ras and
an siRNA against p53 could reduce p53 levels in human lung cancer
CAFs more than in normal lung fibroblasts [147]. These data suggest
a CAF-specific susceptibility to secreted factors from preneoplastic cells
compared with normal fibroblasts, facilitating inhibition of the p53
non–cell-autonomous tumor suppressor function in CAFs. Similarly,
our unpublished data indicate that conditioned medium from mutant
H-Ras transformed ovarian surface epithelial cells selectively suppressed
p53 in otherwise normal ovarian fibroblasts. Therefore, it can be stated
that because tumor suppressor activity in the normal ovarian or fallopian
tube stroma exerts an inhibitory influence on ovarian neoplastic initia-
tion and progression, attenuation of p53 activity in the ovarian reactive
stroma would strongly favor tumorigenic progression.
Disruption of Stromal Intracellular Signaling
Pathways by Cancer Cell Communication:
Who Is Implicated?
Epigenetic modification of signaling pathways related to secretion in
CAFs is a field in which many questions remain to be answered, but
several target pathways in CAFs of various tumor tissue types point to
a role for epigenetic modification in ovarian CAFs promoting ovarian
cancer development. Within invasive and aggressive gliomas, tenascin-
C is upregulated in stromal cells by recombination binding protein Jκ
(RBPJκ), a Notch 2 cofactor for transcription in activated Notch signal-
ing [148]. Thus, RBPJκ may facilitate intracellular signaling pathway
interpretation of secreted epithelial-stromal cell communication (Fig-
ure 3B). In addition to signaling pathways directly activated by mole-
cules secreted by CAFs, the mechanical stress generated during ECM
modification by breast CAF-secreted factors may play a role in activat-
ing signaling pathways in mammary carcinoma cells, contributing to
disease progression and compromised disease treatment [149]. Thus,
the changing force exerted by the CAF-remodeled ECM on ovarian
cancer cells needs to be considered to fully delineate the process of
tumor progression. Interestingly, tenascin-C induction in lung fibro-
blasts depends on RhoA/RhoA–dependent kinase/integrin-linked
kinase–mediated signaling in response to mechanical shear stress, al-
though this pathway does seem to be bypassed through extracellular
signal–regulated kinase 1/2 and PKB/Akt signaling [150].
Several recent publications have presented preliminary gene expres-
sion profiling data that have identified several secreted target proteins
that control microenvironmental cross-talk, guidance, and remodeling
(e.g., plasminogen activator inhibitor-2, dickkopf-related protein 1,
t-type plasminogen activator) that were upregulated in breast CAFs,
which likely to play a role in communicating with, and promoting the
aggressiveness of, breast cancer cells [40,151]. It is highly likely that a
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similar expression profiling study of ovarian CAFs would yield signifi-
cant potential targets for therapeutic intervention.
Modeling Ovarian Cancer Epithelial-Stromal
Cell-Cell Interaction
Despite our familiarity with characterized genetic alternations in ovarian
cancer epithelial cells, we do not yet fully recognize how these genetic
changes work together to not only transform normal ovarian surface epi-
thelial cells into cancerous cells but also facilitate and recruit an activated
stromal microenvironment. In addition, the inherent difficulties in ac-
cessing and deriving normal and cancer–associated ovarian fibroblast cell
lines makes studying cross-talk between the stroma and epithelium in
advanced ovarian cancer very challenging. Similarly, as ovarian carci-
noma likely originates from heterogeneous origins, there is a paucity
of research investigating stromal-epithelial interactions during tumor
initiation in the ovary. Multiple seminal publications using murine
model systems for studying ovarian carcinoma development have done
so primarily through the introduction mutant K-Ras, c-Myc, or Akt
onto a mutated p53 or PTEN background [152–154]. Developing
models using human ovarian surface epithelial cells or human fallopian
tube epithelial cells has proven a difficult task. Expression of SV40 large
Tand small t antigens genomic regions [155,156], or human papilloma-
virus type 16E6/E7 region [157], extended the cellular replication life of
human ovarian surface epithelial cells, yielding marginal transformation
and growth in anchorage-independent colony assays as well as nude
mouse tumor growth. Recently, a promising ex vivo model was devel-
oped using human fallopian tube epithelial cells in the hopes of even-
tually building a model of late-stage serous ovarian carcinoma [158].We
have developed a genetically defined mouse xenograft model of ovarian
carcinoma by expressing the catalytic subunit of human telomerase, on-
cogenic HRAS or KRAS mutants along with SV40 T/t antigens that
yielded subcutaneous tumor formation and intraperitoneal ascites with
corresponding CA125/mesothelin staining [62]. We refined this model
further by replacing SV40 expression with inhibitory constructs knock-
ing down p53 or Rb, allowing for stepwise delineation of oncogenic and
transformative events inmodeling ovarian carcinoma [159,160]. There-
fore, existing models such as these allow for investigation into the un-
derlying molecular mechanisms correlated with ovarian or fallopian
epithelial cell specification, as well as stage-specific signaling mecha-
nisms, in studying and modeling ovarian cancer.
In murine or in vitromodels focusing on the role and contribution of
stroma in ovarian cancer development, much work remains. A few ex-
isting publications directly address the ovarian stromal mechanisms pro-
moting ovarian tumorigenesis. Recently, a murine ovarian carcinoma
cell line stably overexpressing a fluorescent-tagged vascular endothelial
growth factor 164 isoform was developed, which demonstrated signifi-
cantly accelerated tumor growth with ascites formation, elevated tumor
angiogenesis, and promotion of tumor cell survival relative to controls
[161]. Thus, ovarian tumor cells within this model directly modulate
their proximal tumor stromal microenvironment in promoting tumor-
igenesis and vascular support and may prove useful for future studies
with therapeutic agents targeting the endothelial cell–specific stromal
microenvironment contribution to tumor growth. Moreover, another
recent study used mouse modeling to focus on ovarian stroma con-
tribution and identified that the cell-cell interaction between ovarian
epithelial cells and host stroma was an important factor in ovarian
tumorigenesis [162]. Furthermore, we have used our Ras-mediated
ovarian cancer mouse xenograft model to demonstrate that GRO-α–
expressing senescent ovarian fibroblasts significantly promoted xeno-
graft tumorigenesis of preneoplastic ovarian surface epithelial cells
[63]. Thus, the scarcity of existing models allowing characterization of
the role of ovarian CAFs in promoting ovarian cancer epithelial tumor
growth indicates the real need for development in this field.
Conclusions and Future Work
Although progress has been made toward understanding the role
of CAFs in ovarian tumorigenesis, many questions remain. Potential
therapeutic targets of cancer- activated stromal signaling pathways that
act as regulatory switches for tumor-promoting molecules have been
identified—for example, IL-1β/IL-1R1, SDF-1α/CXCR4, GROα-1/
CXCR-2, NF-κB p65, and tenascin-C—but detailed mechanisms re-
main to be worked out. An area of critical importance is deciphering
the mechanism by which p53 or other tumor suppressors are inhibited
in ovarian fibroblasts and the downstream mediators of this inhibition,
which activate the expression of secretory tumor cell behavioral modu-
lators like SDF-1α and FAP-1α (Figure 3B). Whether by genetic alter-
ation of tumor suppressors in cancer stroma or by cross-signaling that
upregulates key paracrine pathways that stimulate cell growth, successful
tumor initiation and evasion of immune surveillance probably depend
on proximal stromal activation. Thus, continuing to investigate the role
of CAFs in ovarian cancer development should be a high priority for
future work. Furthering our understanding of the contribution of acti-
vated stromal signaling pathways to ovarian tumorigenesis may yield
specific intracellular signaling targets, which effectively suppress the
contribution of cancer-associated stromal cells to malignancy, and also
novel cancer stromal markers for early detection of ovarian cancer.
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